Anti-Vir-Biota o. T.
Bevorratungen vieler Länder mit dem Anti-Vir-Produkt Relenza als Vorbeugung gegen die Vögelgrippe zu greifen.
Heute starker Zuwachs an der Börse in Australien-+7,65%-bei hohem Umsatz.
Auch Frankfurt zieht an. Kauf wärmstens empfohlen!
Code Last % Chg Bid Offer Open High Low Vol
BTA 1.760 7.65% 1.740 1.765 1.640 1.770 1.640 3,008,260
18:50:13 1,09 10.700
18:03:33 1,09 13.000
17:16:34 1,09 5.000
17:00:14 1,09 3.850
16:44:58 1,09 4.000
16:39:33 1,09 14.300
16:20:01 1,08 2.752
15:42:49 1,08 8.850
15:41:36 1,09 4.300
15:24:50 1,08 18.828
15:14:10 1,08 14.072
14:35:08 1,08 5.828
14:32:58 1,08 3.000
14:28:18 1,07 2.000
Times & Sales
Zeit Kurs Stück
14:27:22 1,06 0
14:27:21 1,06 0
14:27:05 1,07 2.000
14:24:08 1,08 6.850
14:23:41 1,07 2.000
14:18:23 1,07 5.000
14:04:14 1,08 2.250
13:47:43 1,08 3.000
13:31:15 1,08 3.020
13:22:12 1,08 13.500
13:13:59 1,08 1.500
12:59:06 1,08 3.300
12:45:03 1,09 3.000
12:43:24 1,09 17.200
12:32:06 1,09 1.750
Seite: 1 2 # 1# 2
Code Last % Chg Bid Offer Open High Low Vol
BTA 1.780 1.14% 1.765 1.780 1.790 1.790 1.755 808,781
in Japan
Melbourne Australia—Wednesday 29 March 2006.
Biota today confirmed that its joint venture partner, Sankyo Co. Ltd intends to
develop, manufacture and market the jointly owned influenza treatment, LANI, for
the Japanese market.
LANI is a next generation, long acting neuraminidase inhibitor (LANI) with higher
potency and longer duration of action than other existing influenza antivirals. These
properties make LANI ideal for stockpiling against the threat of a potential avian
influenza pandemic, as well as for treatment and prevention of seasonal influenza.
Commenting on the Sankyo decision today, Biota Chief Executive Officer, Peter
Cook, said, “We believe LANI will change the dynamics of the influenza antiviral
market, which is currently dominated by Tamiflu. LANI will have significant
advantages over the current influenza antivirals. Sankyo’s decision to become the
commercial partner of LANI for Japan demonstrates their commitment and
confidence in the LANI program.”
Sankyo will meet the full cost of the accelerated program for Japan, which is the
largest market for seasonal influenza treatments. Sankyo’s decision to develop LANI
for Japan is expected to create strong interest for licensing the products in the rest
of the world. Biota and Sankyo are entitled to equally share all licensing, milestone
and royalty fees received by the joint venture.
Today’s announcement follows Biota’s recent licensing and collaboration agreement
with MedImmune for the development and commercialisation of Biota’s drugs for the
prevention and treatment of RSV infection (which can cause serious illness and even
death in infants), and the commencement of a Phase I clinical study of its drug for
the treatment and prevention of rhinovirus (a cause of the common cold).
http://www.biota.com.au/announcements/2006/...flu_treatment_Japan.pdf
Gruß Hausi
übewunden. Hoher Umsatz. Zugreifen jetzt noch empfehlenswert, bevor Sprung nach oben kommt! 1,83Aus$~1,137€
29.03.06:
Code Last % Chg Bid Offer Open High Low Vol
BTA 1.830 2.81% 1.820 1.830 1.790 1.835 1.790 3,360,637
Zum Einsteigen noch genügend Luft nach oben.
Code Last % Chg Bid Offer Open High Low Vol
BTA 1.905 4.1% 1.905 1.910 1.845 2.000 1.845 13,731,078
neue bzw. weiterentwickelte Produkte in der Pipeline und u.a. mit Glaxo-Smith, Sankyo und Medimmune potente Vertriebs- und Entwicklungspartner weltweit.
-LANI: Neuartiges universelles Grippemittel-auch gegen Vogelgrippe mit deutlichen Vor-
teilen hinsichtlicht Wirkungskraft und-dauer i.Vgl.zum marktführenden Blockbuster Tamiflu. Mit Sankyo für den japanischen-weltweit umsatzstärksten- Markt und Aussicht auf globale lukrative Lizenzvergaben. 50% Biota-Anteil am Erlös!
-Medikament gg. RSV (schwere Kinderkrankheit) gemeinsam mit Medimmune.
-Phase I-kinische-Studie für Schnupfenmedikament.
Zf.: Höchst effektives erfolgversprechendes Potential zur Bekämpfung von Massenkrankheiten, z.T.mit neuartigen Wirkungsmechanismen.
nachzulesen (in Englisch): www.biota.com.au s.a. Beitrag (engl.) Ebundy vom 29.03.06.
vorläufiges Kursziel ca.: 1,9
13:39:21 1,13 4.464
12:29:34 1,12 3.500
12:26:22 1,11 2.250
12:12:22 1,11 5.000
11:58:53 1,11 1.000
10:53:29 1,11 2.300
10:40:14 1,11 2.500
Thursday March 30, 2006, 5:05 pm
The US government has approved the use of Australian company Biota Holdings Ltd's flu drug Relenza to prevent influenza.
The US Food and Drug Administration on Wednesday approved the use of the antiviral drug by adults and children aged five and over to prevent influenza A and B.
Biotechnology company Biota said Relenza, which has previously been approved for the treatment of the flu, will now also be available for its prevention.
"Biota shareholders should see this as a welcome extension of indications for Relenza, further opening up marketing opportunities in the key North American market," Biota chief executive Peter Cook said.
A spokeswoman for Biota said the drug could be used to fight bird flu, which is a strain of influenza A.
Earlier this month the US Department of Health and Human Services (HHS) ordered 2.2 million courses of Relenza from global pharmaceutical giant GlaxoSmithKline (GSK) in addition to the 1.75 million courses already ordered.
The government has been stockpiling antiviral drugs for use in the event of a potential influenza pandemic.
Biota licences Relenza to GSK and receives a royalty of seven per cent on its sales.
The Melbourne-based company said the US, Australian, French and German governments are stockpiling Relenza in case of outbreak of avian flu.
The US has already gathered 5.5 million courses of antiviral drugs, including a rival drug - Tamiflu - made by Roche.
Biota shares rose 7.5 cents or four per cent to $1.905.
Quelle:http://au.biz.yahoo.com/060216/30/jj8a.html
BTA 1.850 -2.89% 1.850 1.860 1.925 1.935 1.830 3,776,518
die meldungen bisher waren auf jeden fall ermutigend.
Im Zuge der weiteren Eskalation der Vögelgrippe-PAN-Epedemie-Gefahr-s.auch aktueller Nutztier-Befall in Sachsen-werden im Zuge der Notfallpläne der Länder die Vorräte
an Gegenmitten stark erhöht. So am Beispiel Saarland um ca. 500%. s.Artkel der Saarbrücker Zeitung von heute.
Doch all diese Anstrengungen werden im Falle einer Pandemie nicht ausreichen, die Nachfrage nach Impfstoff zu decken, weshalb auch viele kleine Biotechs von der Einlagerung von Impfstoffen profitieren könnten. Einige, die ich schon vor längerer Zeit vorgestellt habe, konnten bereits von der Bedrohung profitieren, anderen steht dies noch bevor. Besonders interessant ist auch ein kleines australisches Unternehmen, welches sich auf die Produktion eines Impfstoffes gegen H5N1 fokussiert hat.
Erst kürzlich hat das Unternehmen ermutigende Ergebnisse einer Studie vermelden können. Als Alternative zum Impfstoffmangel setzt die Firma auf ein Produkt, das in deutlich geringerer Menge verabreicht wird und dennoch einen optimalen Impfschutz bietet. Den letzten Studienergebnissen zufolge man nun tatsächlich eine solche optimale Dosis, die deutlich unter der herkömmlich verabreichten Dosis liegt, finden. Bei ungefähr der Hälfte der Studienteilnehmer konnte ein ausreichender Schutz mit einer Dosis von nur 15 Mikrogramm des viralen Antigens erreicht werden.
Damit schneidet der Impfstoff deutlich besser ab als der von Sanofi Pasteur, dessen experimenteller Impfstoff erst bei einer Gabe von 30 Mikrogramm des viralen Antigens ausreichenden Schutz gegen das Vogelgrippevirus zeigte. Damit kämen im Falle einer Pandemie deutlich mehr Menschen in den Genuss einer Impfung, welche sich dann wohl eine große Nachfrage erfreuen dürfte.
Melbourne Australia—19 April 2006.
Biota Holdings Limited (ASX:BTA) today advise that the US Department of Defense
have awarded GlaxoSmithKline a contract for Relenza. Biota receives a royalty of
7% on all GSK sales of Relenza.
An extract of a News Release from the US Department of Defense, Office of the
Assistant Secretary of Defense (Public Affairs) dated 12 April 2006 is as follows:
“GlaxoSmithKline (GSK), Philadelphia, Pa., is being awarded a maximum $5,248,986
firm fixed price requirements contract for zanamivir inhalation (relenza) packages for
Army, Navy, Air Force, and Marine Corps. There were 2 proposals solicited and 2
responded. Date of performance completion is March 31, 2007. The contracting
activity is the DSCP, Philadelphia, Pa. (SP0200-06-D-0001).”
The full release is available at: www.dod.mil/contracts.
GlaxoSmithKline has confirmed the order to Biota.
About Biota
Biota is a world-leading antiviral drug discovery company based in Melbourne, with
key expertise in viral respiratory diseases, particularly influenza. Biota developed
the first-in-class neuraminidase inhibitor drug, zanamivir, (Relenza) and through a
partnership with GlaxoSmithKline (GSK) brought it to market. Relenza is currently
being stockpiled by various governments for defense against avian influenza.
Work has been underway at Biota for some time to develop a new generation of
neuraminidase inhibitors designed to be more active and longer acting than the first
generation products.
Biota also collaborated with Inverness Medical to develop the FLU OIA influenza
diagnostics range for the rapid detection of influenza, which has been marketed
since 1999.
™Relenza is a registered trademark of the GlaxoSmithKline group of companies
®FLU OIA is a registered trademark of Thermo Electron Corporation
*Further information available at www.biota.com.au.
Investor / Analyst Enquiries Media Enquiries
Peter Cook: T: + 61 3 9915 3720 Tim Duncan / Nerida Mossop
Damian Lismore: T: + 61 3 9915 3721 Hinton & Associates
T: +61 3 9600 1979
For Immediate Release